Anemia Clinical Trial
Official title:
Delayed Versus Immediate Cord Clamping and Changes in Neonatal Hemoglobin
The purpose of this study is to determine whether the timing of the clamping of the umbilical
cord after delivery has an impact on neonatal hemoglobin and hematocrit, tests that determine
the number of red cells in the blood and their ability to carry oxygen. The study hypothesis
is that delaying cord clamping until cord pulsation has ceased will increase the neonatal
blood volume and thereby increase the hemoglobin and hematocrit.
We propose to recruit 150 women who present for vaginal delivery at Tulsa Regional Medical
Center. Half of the women will be randomly assigned to the immediate clamping group, which
will entail clamping of the umbilical cord within six seconds of delivery of the fetal
shoulders. The other half of the volunteers will be assigned to the delayed clamping group,
which will entail clamping the cord after a palpable pulse has ceased, or after 10 minutes.
The infants of mothers in both groups will have blood drawn for a hemoglobin and hematocrit
at the time of the routine PKU heel stick, usually is performed within 18-24 hours of
delivery.
Statistical differences between the blood counts of infants in the control and study groups
will be compared using independent samples t tests.
The purpose of this study is to determine whether the timing of the clamping of the umbilical
cord after delivery has an impact on neonatal hemoglobin and hematocrit, tests that determine
the number of red cells in the blood and their ability to carry oxygen. The study hypothesis
is that delaying cord clamping until cord pulsation has ceased will increase the neonatal
blood volume and thereby increase the hemoglobin and hematocrit.
As the communication between the placenta and fetus, the umbilical cord provides oxygen and
nutrients until the time of delivery. Even after delivery, placental respiration continues
for a short time and the newborn infant continues to receive blood from the placenta until
physiologic closure of the cord vessels terminates the transfusion. While most term infants
can tolerate variations in blood volume, those who are compromised by prematurity, cesarean
delivery or cord compression in utero may require blood transfusions if the cord is clamped
before pulmonary perfusion is established. Delayed cord clamping is believed to provide a
greater supply of blood to perfuse the lungs without robbing blood from the other organs.
In uncomplicated vaginal deliveries the umbilical cord traditionally has been clamped
immediately after delivery, more for the doctor's convenience than for any consideration
regarding the health of the infant. Both immediate and delayed cord clamping are accepted as
routine standard of care at delivery, depending on the circumstances. However, some
clinicians and researchers have suggested that by delaying the clamping of the umbilical
cord, the placental transfusion to the newborn is maintained, optimizing blood volume and
hemostasis.
Several European research studies have suggested that delayed cord clamping increases newborn
hemoglobin and hematocrit. However, these studies were not performed under properly
controlled conditions and thus have failed to gain general acceptance.
We propose to recruit 150 women who present for vaginal delivery at Tulsa Regional Medical
Center. We believe this number of volunteers is possible to enroll in the allotted five
months for data collection. A power analysis for this sample size was performed by Dr. Mark
Payton, professor of statistics at the OSU Stillwater campus. He estimated that a difference
of 0.3 standard deviations has a power of just over 95%.
OSU medical students will explain the study and recruit patient volunteers during routine
third trimester prenatal care visits at the OSU OB/Gyn resident clinic at Houston Parke.
Study investigators Drs. Beal and Carnett will determine the eligibility of those patients
who agree to participate. The ethnic mix of the resident clinic population is not available
because race information is not routinely entered in the MegaWest Practice Management Program
currently in use.
When a volunteer presents for delivery, the resident in charge of the labor and delivery unit
will remind the patient of her previous consent to participate and assign her to either the
control group or the study group in an alternating fashion. Women who have agreed to
participate in the study will have an identifying mark on their prenatal records which are
sent from the clinic. In the control group, the umbilical cord will be clamped immediately
after delivery. In the study group, the umbilical cord will be clamped once cord pulsation
ceases. Patients also will be advised at this time that they can withdraw from the study at
any time, regardless of the reason. The physician making group assignments and performing
deliveries on a given day may not be one of the study investigators.
The inability to mask the patients and study personnel will not affect the outcome of the
study as strict guidelines regarding the timing of cord clamping will be applied. Immediate
clamping will entail clamping of the umbilical cord within six seconds of delivery of the
fetal shoulders. Delayed clamping will be performed by clamping the cord after a palpable
pulse has ceased, or after 10 minutes. Cord pulsation generally stops within two minutes of
delivery. The physician performing the delivery will determine when cord pulsation stops and
the clamp times, immediate or delayed will be recorded by delivery room personnel who
routinely record times of delivery of infant, delivery of placenta, infant weight and APGARs.
Therefore, prior knowledge of group assignment will not affect the behavior of the patient or
the physician at the time of delivery.
The infants of mothers in both groups will have blood drawn for a hemoglobin and hematocrit
at the time of the routine PKU heel stick. There will be no additional heel sticks to collect
blood. The PKU test usually is performed within 18-24 hours of delivery. All infant study
data will be collected at this time and no further blood draws will be necessary. The total
amount of blood drawn from the baby will be approximately 8-10 drops, or about two teaspoons,
which will include blood for the PKU test and the study tests. The results of the blood tests
will then be analyzed and compared between the two groups. This comparison will also involve
analysis of the mothers' admitting hemoglobin and hematocrit, blood type and demographic
data, including age and smoking history, to look for possible exclusion or confounding
factors. Maternal blood is routinely tested at the time of admission for blood type,
hemoglobin and hematocrit. This involves the collection of approximately two test tubes of
blood. No additional testing or blood collections will be performed on participating mothers
other than those routinely done.
There are no increased risks to mothers or their infants who agree to participate in the
study. Likewise, there are no direct benefits to participation to either mothers or babies
aside from the contribution their participation makes in furthering medical knowledge.
Adverse events and serious adverse events will be recorded and reported to the IRB under the
policies and procedures provided by OSUCHS.
Our tentative timetable is to recruit 25 patients per month so that the data collection can
be completed within five months. Tulsa Regional typically delivers about 1,000 babies
monthly. Approximately 23 percent of these deliveries are cesarean sections. Of the remaining
deliveries, it is reasonable to estimate that 25 patients per month could be recruited to the
study.
The study population will include 150 women and their newborn infants delivered at Tulsa
Regional Medical Center. Mothers must be between the ages of 18 and 34 and be full term, 37
to 41 weeks, with a singleton pregnancy at the time of delivery. Women will be excluded from
the study if their delivery is complicated by non-reassuring fetal heart tones, preeclampsia,
eclampsia, chronic hypertension, meconium-stained amniotic fluid, fetal anomalies or any
other condition which could require immediate newborn evaluation by nursery personnel at the
time of delivery. Infants requiring operative delivery by forceps or vacuum also will be
excluded.
Analysis Statistical differences between the blood counts of infants in the control and study
groups will be compared using independent samples t tests.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
| Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
| Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
| Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
| Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
| Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
| Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
| Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
| Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
| Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
| Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
| Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
| Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
| Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 |